Today: 9 April 2026
Tesla stock slides 4% after Musk flags “agonizingly slow” Cybercab, Optimus ramp
21 January 2026
2 mins read

Tesla stock slides 4% after Musk flags “agonizingly slow” Cybercab, Optimus ramp

New York, January 21, 2026, 09:44 (ET) — Regular session.

  • Tesla shares dropped roughly 4% in early trading
  • Musk warns the first Cybercab robotaxi and Optimus production will crawl—“agonizingly slow,” he says
  • Investors are eyeing Jan. 28 earnings for clues on margins, spending, and autonomy timelines

Tesla (TSLA) shares dropped 4.2% to $419.25 in early Wednesday trading after CEO Elon Musk warned that initial production of the Cybercab robotaxi and Optimus humanoid robot would be “agonizingly slow” before picking up pace. The company, valued around $1.39 trillion, has pinned much of its future on these ambitious projects to shift investor perception beyond just electric vehicles. Musk explained on X that production speed slows as new parts and processes are introduced; the Cybercab is a two-seater lacking manual controls, with Tesla aiming for volume production by 2026 while testing robotaxi service in Austin using a version of its Full Self-Driving software. Reuters

That choice of words is critical since the stock’s premium hinges on timing. When Musk expresses caution about the ramp-up, it signals a warning: the next phase remains mostly about engineering, not revenue.

Tesla has urged investors to ignore the weaker EV market and zero in on its software and automation segments, though those remain relatively minor. Shares have been volatile ahead of the upcoming earnings report, with traders ready to sell off at the slightest sign of delayed timelines.

Cost-cutting is back in focus in Europe. Tesla has trimmed about 1,700 jobs at its Berlin gigafactory, Handelsblatt reported, citing an internal document linked to works council elections. The plant now employs 10,703 people. A Tesla spokesperson didn’t immediately respond to requests for comment. Back in April 2024, Musk told employees the company planned to slash over 10% of its global workforce to boost productivity and cut costs. Reuters

The broader market wasn’t much kinder. Tesla, part of the “Magnificent Seven” tech giants, dipped Tuesday as President Donald Trump’s tariff threats sparked a risk-off mood. Investors turned to safe havens like gold and silver. Wedbush analysts, led by Dan Ives, called the pullback a buying opportunity for “tech winners” in 2026. UBS, meanwhile, stuck to its bullish stance on global equities despite the volatility. Investopedia

Musk has turned the spotlight back to compute. He mentioned that Tesla aims to bring Dojo3 back to life for “space-based AI compute,” TechCrunch reports. TechCrunch

Tesla reported delivering more than 418,000 vehicles in Q4 and deployed 14.2 gigawatt-hours (GWh) of energy storage products. (One GWh equals a billion watt-hours.) The company plans to release its quarterly results after the market closes on Jan. 28, followed by a Q&A webcast at 5:30 p.m. Eastern. SEC

Investors dialed in will push for details on automotive margins and pricing, seeking signs that cost-cutting measures are reflecting in the results. They’ll also demand specifics on Cybercab and Optimus — exact timelines, capacity figures, and the key factors that need to align.

The downside is clear. U.S. auto safety regulators have pushed back Tesla’s deadline to respond in their probe about possible traffic law violations while Full Self-Driving was active, now set for Feb. 23. Increased scrutiny could throw a wrench in Tesla’s plans to roll out robotaxis on a larger scale. Reuters

The stock is currently caught between ambition and execution. The next trigger point: Tesla’s Jan. 28 earnings report, which will shed light — or not — on Cybercab, Optimus, and Full Self-Driving.

Stock Market Today

  • AbbVie's Humira Launch on TrumpRx with 86% Discount Sparks Valuation Questions
    April 9, 2026, 9:02 AM EDT. AbbVie (NYSE:ABBV) has introduced Humira on the TrumpRx platform at an 86% discount under a White House pricing deal aiming to reduce patient costs and widen drug access. This marks a significant US pricing strategy shift post exclusivity for Humira, a key immunology therapy driving substantial revenue. The stock trades near $206.69, about 20% below analyst targets and 43.8% under fair value estimates. The deep discount could alter patient volume, payer ties, and pricing benchmarks in government-linked drug programs. AbbVie's revenue exposure of $61.2 billion and a high price-to-earnings ratio of 87.3 place focus on potential impacts to cash flow and dividends amid its debt load. Investors should monitor reactions from payers, competitors, and capital markets to this pricing shift that could redefine AbbVie's US market dynamics.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Netflix stock slides premarket as Warner Bros deal costs eclipse an earnings beat
Previous Story

Netflix stock slides premarket as Warner Bros deal costs eclipse an earnings beat

Nvidia stock (NVDA) ticks up after Tuesday hit as Congress export vote and China trip loom
Next Story

Nvidia stock (NVDA) ticks up after Tuesday hit as Congress export vote and China trip loom

Go toTop